BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 9203083)

  • 1. Attenuation of levodopa-induced toxicity in mesencephalic cultures by pramipexole.
    Carvey PM; Pieri S; Ling ZD
    J Neural Transm (Vienna); 1997; 104(2-3):209-28. PubMed ID: 9203083
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Both the antioxidant and D3 agonist actions of pramipexole mediate its neuroprotective actions in mesencephalic cultures.
    Ling ZD; Robie HC; Tong CW; Carvey PM
    J Pharmacol Exp Ther; 1999 Apr; 289(1):202-10. PubMed ID: 10087005
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Partial purification of a pramipexole-induced trophic activity directed at dopamine neurons in ventral mesencephalic cultures.
    Ling ZD; Tong CW; Carvey PM
    Brain Res; 1998 Apr; 791(1-2):137-45. PubMed ID: 9593863
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dopamine D3 receptor-preferring agonists induce neurotrophic effects on mesencephalic dopamine neurons.
    Du F; Li R; Huang Y; Li X; Le W
    Eur J Neurosci; 2005 Nov; 22(10):2422-30. PubMed ID: 16307585
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bromocriptine protects dopaminergic neurons from levodopa-induced toxicity by stimulating D(2)receptors.
    Takashima H; Tsujihata M; Kishikawa M; Freed WJ
    Exp Neurol; 1999 Sep; 159(1):98-104. PubMed ID: 10486178
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pramipexole attenuates the dopaminergic cell loss induced by intraventricular 6-hydroxydopamine.
    Vu TQ; Ling ZD; Ma SY; Robie HC; Tong CW; Chen EY; Lipton JW; Carvey PM
    J Neural Transm (Vienna); 2000; 107(2):159-76. PubMed ID: 10847557
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Catechol-O-methyltransferase inhibition protects against 3,4-dihydroxyphenylalanine (DOPA) toxicity in primary mesencephalic cultures: new insights into levodopa toxicity.
    Blessing H; Bareiss M; Zettlmeisl H; Schwarz J; Storch A
    Neurochem Int; 2003 Jan; 42(2):139-51. PubMed ID: 12421594
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neuroprotection by pramipexole against dopamine- and levodopa-induced cytotoxicity.
    Zou L; Jankovic J; Rowe DB; Xie W; Appel SH; Le W
    Life Sci; 1999; 64(15):1275-85. PubMed ID: 10227583
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pramipexole has astrocyte-mediated neuroprotective effects against lactacystin toxicity.
    Imamura K; Takeshima T; Nakaso K; Ito S; Nakashima K
    Neurosci Lett; 2008 Aug; 440(2):97-102. PubMed ID: 18555604
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Catechol-O-methyltransferase inhibition attenuates levodopa toxicity in mesencephalic dopamine neurons.
    Storch A; Blessing H; Bareiss M; Jankowski S; Ling ZD; Carvey P; Schwarz J
    Mol Pharmacol; 2000 Mar; 57(3):589-94. PubMed ID: 10692500
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of dopamine neuron firing by pramipexole, a dopamine D3 receptor-preferring agonist: comparison to other dopamine receptor agonists.
    Piercey MF; Hoffmann WE; Smith MW; Hyslop DK
    Eur J Pharmacol; 1996 Sep; 312(1):35-44. PubMed ID: 8891576
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparable Neuroprotective Effects of Pergolide and Pramipexole on Ferrous Sulfate-Induced Dopaminergic Cell Death in Cell Culture.
    Reichelt D; Radad K; Moldzio R; Rausch WD; Reichmann H; Gille G
    CNS Neurol Disord Drug Targets; 2016; 15(10):1325-1332. PubMed ID: 27488420
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neuroprotective effects of the dopamine D2/D3 agonist pramipexole against postischemic or methamphetamine-induced degeneration of nigrostriatal neurons.
    Hall ED; Andrus PK; Oostveen JA; Althaus JS; VonVoigtlander PF
    Brain Res; 1996 Dec; 742(1-2):80-8. PubMed ID: 9117424
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of neurotoxicity following repeated administration of l-dopa, d-dopa and dopamine to embryonic mesencephalic dopamine neurons in cultures derived from Fisher 344 and Sprague-Dawley donors.
    Alexander T; Sortwell CE; Sladek CD; Roth RH; Steece-Collier K
    Cell Transplant; 1997; 6(3):309-15. PubMed ID: 9171163
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Toxic effects of L-DOPA on mesencephalic cell cultures: protection with antioxidants.
    Pardo B; Mena MA; Casarejos MJ; Paíno CL; De Yébenes JG
    Brain Res; 1995 Jun; 682(1-2):133-43. PubMed ID: 7552304
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor necrosis factor alpha is toxic to embryonic mesencephalic dopamine neurons.
    McGuire SO; Ling ZD; Lipton JW; Sortwell CE; Collier TJ; Carvey PM
    Exp Neurol; 2001 Jun; 169(2):219-30. PubMed ID: 11358437
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low dose pramipexole is neuroprotective in the MPTP mouse model of Parkinson's disease, and downregulates the dopamine transporter via the D3 receptor.
    Joyce JN; Woolsey C; Ryoo H; Borwege S; Hagner D
    BMC Biol; 2004 Oct; 2():22. PubMed ID: 15473914
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacology of pramipexole, a dopamine D3-preferring agonist useful in treating Parkinson's disease.
    Piercey MF
    Clin Neuropharmacol; 1998; 21(3):141-51. PubMed ID: 9617505
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Toxicity of dieldrin for dopaminergic neurons in mesencephalic cultures.
    Sanchez-Ramos J; Facca A; Basit A; Song S
    Exp Neurol; 1998 Apr; 150(2):263-71. PubMed ID: 9527896
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel neuroprotective mechanisms of pramipexole, an anti-Parkinson drug, against endogenous dopamine-mediated excitotoxicity.
    Izumi Y; Sawada H; Yamamoto N; Kume T; Katsuki H; Shimohama S; Akaike A
    Eur J Pharmacol; 2007 Feb; 557(2-3):132-40. PubMed ID: 17161393
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.